Expensive new post-partum depression pill approved
December 6, 2023
Zurzuvae (zuranolone), a new oral treatment for severe postpartum depression is expected to become available in December. Treatment-resistant postpartum depression poses serious risks to new mothers as well as their children - and in trials Zurzuvae offers quicker relief compared to traditional antidepressants like Prozac and Zoloft. Zurzuvae acts on a different neurohormone than other oral antidepressants, and is in the same class as Zulresso, an intravenous antidepressant approved in 2019 that required a multi-day hospitalization and was rarely used .
Zurzuvae was approved for postpartum depression only; the FDA said it would require additional studies to show it was effective for major depressive disorder, a much larger market. The manufacturer announced a price of $15,900 for the 14-day course of treatment. The drug is regulated as a controlled substance as it can cause dependence.
Implications for employers:
- Mental illness, especially major depression, is a major risk factor for maternal mortality.
- This underscores the need to screen newly pregnant women for depression, both before and after delivery.
- Employers can consider pre- and post-partum PG measures, like this HEDIS measure.
- One recent report suggested that 96% of women of childbearing age lived in geographies with shortages of maternal mental health care.
- An effective medicine for this terrible disease is good news, although the high price of this medication will necessitate restricting its use to those with severe postpartum depression.
- Direct-to-consumer advertising could lead to providers feeling pressured to prescribe this medication for patients who have only moderate postpartum depression.
Thanks for reading. You can find previous posts in the Employer Coverage archive
Please “like” and suggest this newsletter to friends and colleagues. Thanks!
Tomorrow: New obesity drugs will not likely lead to lower overall medical costs